İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

OpenAlex konusu

Advanced Breast Cancer Therapies

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 872 eser 30 yazar konusu

Çalışmalar

872 eser

  1. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  2. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  3. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. 2022
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score…

  4. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    PURPOSE: Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few years. Super…

  5. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 2021
    SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    BACKGROUND: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L…

  6. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 2021
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    BACKGROUND: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L…

  7. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial 2022
    OpenAlex üst %1 OpenAlex 100.0%

    Özet henüz yok.

  8. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.7%

    Özet henüz yok.

  9. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.7%

    Özet henüz yok.

  10. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer 2022
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.8%

    Importance: Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients with extensive-stage small cell lung cancer (SCLC). It remained unknown whether adding a programmed cell death 1 (PD-1) inhibitor to chemotherapy provided similar or better bene…

  11. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study 2021
    SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    BACKGROUND: Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk ear…

  12. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex üst %10 OpenAlex 98.8%

    Özet henüz yok.

Akademisyenler

30 akademisyen